Measuring Omalizumab Responses Using Real-world Evidence (MORRE) Study (MORRE)
21. juni 2021 opdateret af: National Jewish Health
Develop new real-world evidence indicators of worsening and improving asthma. Scientists will measure (1) steps per day, (2) duration and intensity of exercise per day, (3) sleep duration and the number of awakenings per night using Fitbit activity trackers. Scientists will measure asthma symptoms using a once-monthly custom survey delivered to participant smartphones via Twilio. Scientists may measure rescue medication use and adherence to maintenance medications using digital inhaler devices. Scientists will correlate the above measures to participant-reported significant asthma exacerbations (SAEs), lung function (FEV1), and standardized surveys (i.e. the asthma control test (ACT) and global evaluation of treatment effectiveness (GETE)(4)) collected in clinic every 3 months. Coordinators will record any medication changes or reported medication side effects.
Determine response to omalizumab therapy. After participants are placed on omalizumab therapy as part of standard medical care, scientists will determine whether and how real-world evidence can be used to gauge responses to omalizumab. Then, scientists will determine which features, or combination of features, are the best indicators of disease control in the real world.
Studieoversigt
Status
Rekruttering
Betingelser
Undersøgelsestype
Observationel
Tilmelding (Forventet)
50
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Eileen Wang, MD, MPH
- Telefonnummer: 303-270-2796
- E-mail: WANGE@NJHEALTH.ORG
Studiesteder
-
-
Colorado
-
Denver, Colorado, Forenede Stater, 80206
- Rekruttering
- National Jewish Health
-
Kontakt:
- Eileen Wang, MD, MPH
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 85 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
Participants 18-85 years of age with moderate-to-severe asthma at the time of enrollment and eligible for omalizumab therapy.
Beskrivelse
Inclusion Criteria:
- A diagnosis of uncontrolled or difficult-to-treat asthma, defined as 1 course of systemic corticosteroids (e.g. oral prednisone) in the last 12 months OR an asthma control test (ACT) score less than or equal to 19 despite regular use of inhaled corticosteroids (ICS) therapy (at least 176 mcg of fluticasone/day or the equivalent) for at least 1 month prior to enrollment.
- Participants will need access to a smartphone.
Exclusion Criteria:
- Active smoking and any significant comorbid conditions that could inadvertently interfere with study results as determined by the study investigators (i.e. any terminal illness, cancer, HIV, end-stage renal disease, congestive heart failure, severe autoimmune disease or inflammatory bowel disease)
- Conditions that require bursts of oral corticosteroids
- Other significant lung diseases (cystic fibrosis, pulmonary hypertension, interstitial lung disease, pulmonary fibrosis among others)
- Other disease that may mimic asthma, including vocal cord dysfunction, hypersensitivity pneumonitis, or tracheobronchomalacia.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in Asthma Control Test
Tidsramme: Baseline and Week 52
|
Standardized asthma symptom survey
|
Baseline and Week 52
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in Significant asthma exacerbations (SAEs)
Tidsramme: Baseline and Week 52
|
A protocol-defined asthma exacerbation was defined as worsening of asthma symptoms requiring treatment with systemic corticosteroids for 3 or more days; for participants receiving long-term oral corticosteroids, an exacerbation was a 20 mg or more increase in average daily dose of oral prednisone (or a similar dose of another systemic corticosteroid).
The rate of protocol-defined asthma exacerbations, normalized by subject-time at risk and computed over the 24 observation or 52-week treatment period in each treatment group.
|
Baseline and Week 52
|
|
Change From Baseline in Lung Function
Tidsramme: Baseline and Week 52
|
FEV1 % predicted pre- and post-bronchodilator FEV1 absolute (L) pre- and post-bronchodilator FVC % predicted pre- and post-bronchodilator FVC absolute (L) pre- and post-bronchodilator Bronchodilator response: % change in FEV1 after bronchodilator FEV1/FVC ratio: absolute and % predicted Aggregated measure: significant vs non significant bronchodilator reversibility.
Significant reversibility defined as greater than or equal to 12% and 200mL increase in FEV1 or FVC
|
Baseline and Week 52
|
|
Global evaluation of treatment effectiveness (GETE)
Tidsramme: Baseline and Week 52
|
Standard asthma survey that is scored to assess omalizumab responders
|
Baseline and Week 52
|
|
Change From Baseline in Number of Puffs per Day of Beta Agonist Rescue Medication
Tidsramme: Baseline and Week 52
|
Number of inhalations per day averaged out over study duration Number of inhalations per night per month averaged out over study duration
|
Baseline and Week 52
|
|
Change From Baseline in Adherence of Inhaled Corticosteroids
Tidsramme: Baseline and Week 52
|
Doses taken/doses prescribed average out over study duration
|
Baseline and Week 52
|
|
Change From Baseline in Steps Per Day
Tidsramme: Baseline and Week 52
|
Steps per day average out over study duration
|
Baseline and Week 52
|
|
Change From Baseline in Duration of Exercise Per Day
Tidsramme: Baseline and Week 52
|
Minutes exercise per day average out over study duration
|
Baseline and Week 52
|
|
Change From Baseline in Intensity of Exercise Per Day
Tidsramme: Baseline and Week 52
|
Minutes exercise/day x average heart rate during the exercise
|
Baseline and Week 52
|
|
Change From Baseline in Duration of Interrupted Sleep per Night
Tidsramme: Baseline and Week 52
|
Hours of uninterrupted sleep as recorded by Fitbit device
|
Baseline and Week 52
|
|
Change From Baseline in Number of Awakenings per Night
Tidsramme: Baseline and Week 52
|
Number of awakenings per night and/or early morning awakenings as a composite score, as recorded by Fitbit
|
Baseline and Week 52
|
|
Change From Baseline in the Monthly Symptom Questionnaire Scores
Tidsramme: Baseline and Week 52
|
Each answer will be scored 1-10 points, depending on the answer, and added to create a survey score.
Higher scores indicate poorer asthma control.
|
Baseline and Week 52
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
5. februar 2021
Primær færdiggørelse (Forventet)
15. juli 2022
Studieafslutning (Forventet)
15. juli 2023
Datoer for studieregistrering
Først indsendt
22. januar 2021
Først indsendt, der opfyldte QC-kriterier
22. januar 2021
Først opslået (Faktiske)
26. januar 2021
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
23. juni 2021
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
21. juni 2021
Sidst verificeret
1. juni 2021
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- HS-3475
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .